M L Clements-Mann
Affiliation: Johns Hopkins Bloomberg School of Public Health
- Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation GroupM L Clements-Mann
Johns Hopkins University School of Public Health, Baltimore, Maryland, USA
J Infect Dis 177:1230-46. 1998..Trials with ALVAC expressing additional HIV components and rgp120 are underway...
- Lessons for AIDS vaccine development from non-AIDS vaccinesM L Clements-Mann
Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
AIDS Res Hum Retroviruses 14:S197-203. 1998..Clarity about these central issues and adherence to a common vocabulary are important for the process of establishing an appropriate, milestone-driven process for developing safe, effective AIDS vaccines...
- Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutantR A Karron
Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD 21205, USA
Proc Natl Acad Sci U S A 94:13961-6. 1997..The requirement of SH and G for efficient replication in vivo suggests that selective deletion of one or both of these RSV genes may provide an alternative or additive strategy for developing an optimally attenuated vaccine candidate...
- Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infantsM L Clements-Mann
Center for Immunization Research, Department of International Health, School of Public Health, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
Vaccine 19:4676-84. 2001..The efficacy of this quadrivalent rotavirus vaccine needs to be evaluated further...